Pharmaust Limited (AU:NUZ) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurizon Therapeutics Limited has issued 400,000 fully paid ordinary shares following the exercise of unlisted options, priced at $0.10 each. This move, part of their broader strategy to accelerate treatments for ALS and other neurodegenerative diseases, underscores Neurizon’s commitment to advancing its lead drug candidate NUZ-001. The company remains compliant with relevant corporate regulations, ensuring transparency in its financial operations.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.